Alteration of p53 pathway in squamous cell carcinoma of the head and neck: Impact on treatment outcome in patients treated with larynx preservation intent

Journal of Clinical Oncology

Volumn 20, Issue 13, 2002, Pages 2980-2987

  Osman, Iman ^a   Sherman, Eric ^a   Singh, Bhuvanesh ^a   Venkatraman, Ennapadam ^a   Zelefsky, Michael ^a   Bosl, George ^a   Scher, Howard ^a   Shah, Jatin ^a   Shaha, Ashok ^a   Kraus, Dennis ^a   Cordon Cardo, Carlos ^a   Pfister, David G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CELL NUCLEUS; CONTROLLED STUDY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; ORGAN PRESERVATION; PHARYNX CARCINOMA; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARYNGEAL NEOPLASMS; LARYNGECTOMY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHARYNGEAL NEOPLASMS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036645425     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.06.161     Document Type: Article

References (47)

1. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer
2. Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial: EORTC Head and Neck Cancer Cooperative Group
3. The role of chemotherapy in the curative treatment of head and neck cancer
4. p53 analysis of laryngeal cancer in exon 4 to 9
5. Clinical application of proliferating cell nuclear antigen, oncoprotein p53 and tumor front grading analysis in patients operated on for laryngeal cancer
6. Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma
7. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
8. p53-dependent radioresistance in ovarian carcinoma cell lines
9. Nuclear DNA content, an adjunct to p53 and Ki-67 as a marker of resistance to radiation therapy in oral cavity and pharyngeal squamous cell carcinoma
10. Signaling to p53: Breaking the MDM2-p53 circuit
11. Functions of the MDM 2 oncoprotein
12. Regulation of the p53 tumor suppressor protein
13. Tumorigenic potential associated with enhanced expression of gene that is amplified in a mouse tumor cell line
14. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm 2 in tumorigenesis
15. Human p53 restores DNA synthesis control in fission yeast
16. p21 (WAF-1/CIP-1), a downstream regulator of functional p53 loss, in transitional cell carcinoma of urothelium
17. Epidermal growth factor induces cell cycle arrest and apoptosis of squamous carcinoma cells through reduction of cell adhesion
18. Organ-function preservation in advanced oropharynx cancer: Results with induction chemotherapy and radiation
19. Cisplatin, fluorouracil, and leucovorin: Increased toxicity without improved response in squamous cell head and neck cancer
20. TNM staging
21. Concomitant chemotherapy-radiation therapy followed by hyperfractionated radiation therapy for advanced unresectable head and neck cancer
22. Reporting results of cancer treatment
23. Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer, an active regimen for outpatient treatment
24. p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns
25. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer
26. Inactivation of the p53 pathway in prostate cancer: Impact on tumor progression
27. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer
28. Molecular abnormalities of mdm 2 and p53 genes in adult soft tissue sarcomas
29. Nonparametric estimation for incomplete observation
30. Regression models and life-tables
31. A note on quantifying follow-up in studies of failure time
32. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck
33. p53 and Pglycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/radiotherapy
34. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer: Department of Veterans Affairs Laryngeal Cancer Study Group
35. p53 mutation as a prognostic marker in advanced laryngeal carcinoma: Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group
36. Cyclin D1, p53, mdm 2, and Ki67 protein expression in preneoplastic lesions of the larynx
37. The predictive value of p53, MDM-2, cyclin D1 and Ki67 in the progression from low-grade dysplasia towards carcinoma of the larynx
38. Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1
39. MDM2 oncogene as a target for cancer therapy: An antisense approach
40. Expression of ER-D5 and EGFr in laryngeal carcinoma and pre-malignant epithelium
41. Expression of basic fibroblast growth factor and its receptors by head and neck squamous carcinoma tumor and vascular endothelial cells
42. Aberrant p21 (CIP1/WAF1) protein accumulation in head-and-neck cancer
43. Expression of p21 (Waf1/Cip1) in head and neck cancer in relation to proliferation, differentiation, p53 status and cyclin D1 expression
44. p21 (waf) correlates with DNA replication but not with prognosis in invasive breast cancer
45. Relationship of p21 (WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (Pca)
46. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer